Advances in nonsteroidal antiinflammatory drugs and cardiovascular disease

Abstract

Abstract: Nonsteroidal antiinflammatory drugs (NSAIDs) are widely used nowadays, Current evidence indicates significant adverse cardiovascular effects induced by selective COX-2 inhibitors that include increased risk for myocardial infarction, stroke, heart failure, and hypertension.The risk for these adverse effects is likely highest in patients with a prior history of cardiovascular disease, or with high risk of cardiovascular disease.In these patients, use of COX-2 inhibitors for pain relief should be limited to patients for whom there are no appropriate alternatives, and then, only in the lowest dose and for the shortest duration necessary.More long-term data are needed to fully evaluate the extent to which these adverse cardiovascular effects may be offset by the benefits of these medications.More data are also needed on the cardiovascular safety of conventional NSAIDs.It is recommended that both patients and physicians should balance the risks and benefits of NSAIDs.

Key words: nonsteroidal antiinflammatory drugs, cardiovascular disease, adverse effects

CLC Number:

R544.1

ZHU Yu, WU Mei-hua. Advances in nonsteroidal antiinflammatory drugs and cardiovascular disease[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(3): 350-354.

References

[1] Kearney PM, Baigent C, Godwin J, et al.Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials[J].BMJ, 2006,332(7553):1302-1308.
[2] McGettigan P, Henry D.Cardiovascular risk and inhibition of cyclooxygenase:a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2[J].JAMA, 2006, 296(13):1633-1644.
[3] Gislason GH, Jacobsen S, Rasmussen JN, et al.Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction[J].Circulation, 2006, 113(25):2906-2913.
[4] Antman EM, DeMets D, Loscalzo J.Cyclooxygenase inhibition and cardiovascular risk[J].Circulation, 2005, 112(5):759-770.
[5] 李芹, 王睿, 陈马昆.高选择性COX-2 抑制剂罗非昔布撤市分析[J].中国临床药理学与治疗学, 2005, 8(3):259-264.
[6] Grosser T, Fries S, FitzGerald GA.Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities[J].J Clin Invest, 2006, 116(1):4-15.
[7] Belton O, By rne D, Kearney D, et al.Cyclooxygenase-1 and-2-dependent prostacy clin formation in patients with atherosclerosis[J].Circulation, 2000, 102(8):840-845.
[8] Widlansky ME, Price DT, Gokce N, et al.Short-and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension[J].Hypertension, 2003, 42(3):310-315.
[9] Bulut D, Liaghat S, Hanefeld C, et al.Selective cyclooxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension[J].J Hypertens, 2003, 21(9):1663-1667.
[10] BurleighME, Babaev VR, Oates JA, et al.Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice[J].Circulation, 2002, 105(15):1816-1823.
[11] Rott D, Zhu J, Burnett MS, et al.Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice[J].J Am Coll Cardiol, 2003, 41(10):1812-1819.
[12] Fitzgerald GA.Coxibs and cardiovascular disease[J].N Engl J Med, 2004,351(17):1709-1711.
[13] Topol EJ.Failing the public health:rofecoxib, Merck, and the FDA[J].N Engl J Med, 2004,351(17):1707-1709.
[14] Bresalier RS, Sandler RS, Quan H, et al.Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial[J].N Engl J Med, 2005,352(12):1092-1102.
[15] Hippisley-Cox J, Coupland C.Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs:population based nested case-control analysis[J].BMJ, 2005,330(7504):1366.
[16] Graham DJ, Campen D, Hui R, et al.Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs:nested case-control study[J].Lancet, 2005,365(9458):475-481.
[17] Aw TJ, Haas SJ, Liew D, et al.Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure[J].Arch Intern Med, 2005, 165(5):490-496.
[18] HudsonM, Rahme E, Richard H, et al.Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors:A class effect[J] ? Arthritis Rheum, 2007, 57(3):516-523.
[19] Hernandez-Diaz S, Varas-Lorenzo C, Garcia Rodriguez LA.Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction[J].Basic Clin Pharmacol Toxicol, 2006, 98(3):266-274.
[20] White WB, West CR, Borer JS, et al.Risk of cardiovascular events in patients receiving celecoxib:a meta-analysis of randomized clinical trials[J].Am J Cardiol, 2007, 99(1):91-98.
[21] ADAPT Research Group.Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)[J]. PLoS Clin Trials, 2006, 1(7):e33.
[22] McDonald TM, Wei L.Effect of ibuprofen on cardiopro-tective effect of aspirin[J].Lancet, 2003,361(9368):573-574.
[23] Kurth T, Glynn RJ, Walker AM, et al.Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal anti-inflammatory drugs[J].Circulation, 2003, 108(10):1191-1195.
[24] Catella-Lawson F, Reilly MP, Kapoor SC, et al.Cyclooxygenase inhibitors and the antiplatelet effects of aspirin[J].N Engl JMed, 2001,345(25):1809-1817.
[25] US Food and Drug Administration Web Site.Food and Drug Administration Science Paper.Concomitant Use of Ibuprofen and Aspirin:Potential for Attenuation of the Anti-Platelet Effect of Aspirin[S].Available at:http: www.fda.gov cder drug infopage ibuprofen science paper.htm.Accessed January, 29, 2007.
[26] Antman EM, Bennett JS, Daugherty A, et al.Use of nonsteroidal antiinflammatory drugs:an update for clinicians: a scientific statement from the American Heart Association[J].Circulation, 2007, 115(12):1634-1642.